My point is, the inevitable march is driven by the market pipeline created by the Glaxosmithkline, Merck, and Amgen's of the world more than anything else. A good black swan event disrupts this to some extent, but not really. As long as there is a new MRSA, there is a host of new antibiotics being developed. This means there is always an arm race that requires lots of investment, but this pipeline we have set up today is far from optimal. Changing IP rules is a good place to start.